scispace - formally typeset
K

Karen Hoelzer

Researcher at University of Texas MD Anderson Cancer Center

Publications -  6
Citations -  1103

Karen Hoelzer is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chemotherapy & Metastatic breast cancer. The author has an hindex of 3, co-authored 6 publications receiving 976 citations.

Papers
More filters
Journal ArticleDOI

Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer

Gerald Batist, +12 more
- 01 Mar 2001 - 
TL;DR: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.
Journal ArticleDOI

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martin, +622 more
- 01 Dec 2017 - 
TL;DR: 1 year of extended adjuvant therapy with neratinib, administered after chemotherapy and trastuzumab, significantly reduced the proportion of clinically relevant breast cancer relapses-ie, those that might lead to death, such as distant and locoregional relapses outside the preserved breast-without increasing the risk of long-term toxicity.
Journal ArticleDOI

Phase II Study of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Patients With Metastatic Breast Cancer

Edgardo Rivera, +9 more
- 01 Sep 2003 - 
TL;DR: Pgylated liposomal doxorubicin in combination with gemcitabine is active and well tolerated in patients with metastatic breast cancer and represents a therapeutic option for patients receiving front-line therapy for their metastatic Breast cancer.
Journal ArticleDOI

Association between cancer-related fatigue and other symptoms in breast cancer patients.

Anita R. Peoples, +11 more
- 20 May 2013 - 
TL;DR: The association between post-treatment fatigue with disturbed sleep, delayed nausea, age, and baseline fatigue was examined to develop better strategies for the prevention and treatment of cancer-related fatigue.

Phase I I S tudy o f P egylated L iposomal D oxorubicin i n Combination W ith G emcitabine i n P atients W ith M etastatic Breast C ancer

Edgardo Rivera, +9 more
TL;DR: Pegylated liposomal doxorubicin in combination with gemcitabine is active and well tolerated in patients with metastatic breast cancer and represents a therapeutic option for patients receiving front-line therapy for their metastatic Breast cancer.